Characterisation of fluoroquinolone-resistant clinical isolates of Streptococcus pyogenes in Barcelona, Spain  by Rivera, A. et al.
RESEARCH NOTE
Characterisation of fluoroquinolone-
resistant clinical isolates of Streptococcus
pyogenes in Barcelona, Spain
A. Rivera1,2, M. Rebollo1, F. Sa´nchez1,2,
F. Navarro1,2, E. Miro´1, B. Mirelis1,2 and
P. Coll1,2
1Servei de Microbiologia, Hospital de la Santa
Creu i Sant Pau and 2Unitat de Microbiologia,
Departament de Gene`tica i Microbiologia,
Universitat Auto`noma de Barcelona, Barcelona,
Spain
ABSTRACT
Resistance mechanisms and clonal relationships
were determined for six Streptococcus pyogenes
isolates with low- or high-level ciprofloxacin
resistance. Four isolates displayed reduced sus-
ceptibility to ciprofloxacin and levofloxacin and
had alterations in ParC: Ser80 ﬁ Pro (isolate
emm3.1); Ser79 ﬁ Ala (two isolates emm6.0); and
a double substitution Ser79 ﬁ Phe and
Ala121 ﬁ Val (isolate emm12.27). Two isolates
(emm12.26) displayed high-level resistance to
ciprofloxacin and levofloxacin, as well as to other
quinolones. These isolates had the same double
substitution in ParC as isolate emm12.27, and an
additional substitution (Ser81 ﬁ Tyr) in GyrA.
Resistance patterns, emm typing and sequencing
of the quinolone resistance-determining regions
defined two clusters containing three and two
isolates, respectively.
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Fluoroquinolones have excellent in-vitro activity
against Streptococcus pyogenes [1–4], but a low
incidence of isolates with increased ciprofloxacin
MICs (‡ 2 mg ⁄L) has been found in surveillance
studies from Spain and other countries [5–7].
To date, there have been few reports on the
mechanism of fluoroquinolone resistance in
S. pyogenes [8–12], and in these reports, although
some isolates have shown decreased susceptibil-
ity to these drugs, only three isolates have been
described that were highly-resistant to fluoroqu-
inolones [10–12]. The mechanism of fluoroquino-
lone resistance in isolates with decreased
susceptibility has been associated with mutations
in the quinolone resistance-determining region
(QRDR) of parC alone. High-level resistance has
been associated with mutations in the QRDRs of
both parC and gyrA [8–12], and seems to be
analogous to that described in Streptococcus pneu-
moniae and other streptococci [13–18].
The present surveillance study was performed
on quinolone resistance in 189 S. pyogenes isolates
collected from the Hospital Sant Pau (Barcelona,
Spain) between January 1999 and June 2004. S.
pyogenes isolates were identified by conventional
methods [19]. MICs of six quinolones (norfloxa-
cin, ciprofloxacin, levofloxacin, sparfloxacin,moxi-
floxacin and clinafloxacin) were determined by
Etest (AB Biodisk, Solna, Sweden) according to
the manufacturer’s recommendations. Six (3.2%)
isolates with ciprofloxacin MICs of 2 to > 32 mg ⁄L
were detected.
The six resistant isolates were characterised by
emm typing according to the PCR and sequencing
protocol described at the CDC website (http://
www.cdc.gov/ncidod/biotech/strep/strepindex.
html). MICs and emm subtypes of the six isolates
are listed in Table 1. Subtypes emm12.26 and
emm12.27 had not been described previously,
and were assigned to GenBank accession num-
bers AY742804 and AY742805, respectively.
Mutational changes in the QRDRs of the parC,
parE, gyrA and gyrB genes were investigated by
PCR and sequencing. The following primer pairs
were used: 5¢-GGATTGAAACCCGTTCAGCG-3¢
and 5¢-CTGGTAAAACGGTGGGTTCT-3¢ for
parC; 5¢-AAAGCGCGTGATGACTCACG-3¢ and
5¢-TCAGCTCCCACTCCAGCTCC-3¢ for parE;
5¢-TCGTCGTATTCTCTATGGG-3¢ and 5¢-CCC-
TGTCGCTCCATTGACTA-3¢ for gyrA; and
5¢-TTGGAAAACCCACAAGTTGC-3¢ and 5¢-CA-
TCGGCATCGGTCATGATA-3¢ for gyrB. The
amplified sequences were compared with the
GenBank wild-type sequences for each gene
(gyrA, AF220945; gyrB, AE006524; parC,
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AF220946; and parE, AE006540). Four isolates
displayed reduced susceptibility to ciprofloxacin
and levofloxacin, associated with a Ser80 ﬁ Pro
substitution (isolate emm3.1), a Ser79 ﬁ Ala sub-
stitution (two isolates emm6.0), or a double sub-
stitution Ser79 ﬁ Phe and Ala121 ﬁ Val (isolate
emm12.27) in ParC. Except for the amino-acid
change Ser80 ﬁ Pro, not described previously
among streptococci, the other mutations have
been described previously in either S. pyogenes,
S. pneumoniae or the viridans group streptococci
[8–10,16–18,20]. Two isolates (emm12.26) dis-
played high-level resistance to ciprofloxacin
and levofloxacin, as well as other quinolones
(Table 1). These two isolates had the same double
substitution in ParC as isolate emm12.27, and an
additional Ser81 ﬁ Tyr substitution in GyrA.
Identical mutational changes in both parC and
gyrA have been described by Richter et al. [10] in a
S. pyogenes emm12 isolate showing high-level
resistance to fluoroquinolones. In addition, iso-
lates of the same emm type shared several silent
mutations in different positions in three of the
four genes studied (Fig. 1).
Resistance pattern analysis, emm typing and
sequencing of the QRDRs delineated one cluster
(cluster 1) containing two isolates, and a second
cluster (cluster 2) containing three isolates. The
two isolates forming cluster 1 were indistinguish-
able. Cluster 2 included one isolate with reduced
susceptibility to ciprofloxacin (emm12.27) and two
highly-resistant isolates (emm12.26). The two
emm12.26 isolates were indistinguishable. The
emm12.27 isolate differed from the emm12.26
isolates in three nucleotides of the emm region
studied, and lacked the gyrA mutation that
confers high-level ciprofloxacin resistance. These
differences may reflect microevolution of the
circulating clone. An epidemiological relationship
was found only between the two patients from
whom the highly-resistant emm12.26 isolates
belonging to cluster 2 were obtained. These
patients were hospitalised in the same clinical
ward and the isolates were obtained within 72 h
of each other, suggesting possible nosocomial
transmission.
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Fig. 1. Amino-acid changes (bold type) identified in the quinolone resistance-determining regions of (a) the parC gene and
(b) the parE, gyrA and gyrB genes for six fluoroquinolone-resistant Streptococcus pyogenes isolates.
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ABSTRACT
Two amplification tests for the diagnosis of
Chlamydia trachomatis infection, namely the ligase
chain reaction (LCx) and the strand displacement
assay (ProbeTec), were compared using samples
from 1183 patients at sexually transmitted disease
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